Low-Molecular-Weight Heparin and Anti-Xa Targets in Critically Ill Children

2014 ◽  
Vol 15 (7) ◽  
pp. 679-681
Author(s):  
Robert I. Parker
Keyword(s):  
Molecular Weight ◽  
Critically Ill ◽  
Low Molecular Weight Heparin ◽  
Critically Ill Children ◽  
Low Molecular Weight

Higher Doses of Low-Molecular-Weight Heparin (Enoxaparin) Are Needed to Achieve Target Anti-Xa Concentrations in Critically Ill Children*

2014 ◽  
Vol 15 (7) ◽  
pp. e294-e299 ◽  
Author(s):  
Nathan J. Schloemer ◽  
Samer Abu-Sultaneh ◽  
Sheila J. Hanson ◽  
Ke Yan ◽  
Raymond G. Hoffmann ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Critically Ill ◽  
Low Molecular Weight Heparin ◽  
Critically Ill Children ◽  
Low Molecular Weight ◽  
Higher Doses

scholarly journals Low-molecular-weight heparin venous thromboprophylaxis in critically ill patients with renal dysfunction: A subgroup analysis of the PROTECT trial

PLoS ONE ◽  
2018 ◽  
Vol 13 (6) ◽  
pp. e0198285 ◽  
Author(s):  
Menaka Pai ◽  
Neill K. J. Adhikari ◽  
Marlies Ostermann ◽  
Diane Heels-Ansdell ◽  
James D. Douketis ◽  
...  
Keyword(s):  
Molecular Weight ◽  
Renal Dysfunction ◽  
Critically Ill ◽  
Subgroup Analysis ◽  
Critically Ill Patients ◽  
Low Molecular Weight Heparin ◽  
Low Molecular Weight

scholarly journals Antithrombin III Supplementation in a Premature Infant: Is There a Target Antithrombin Level?

2021 ◽  
Vol 26 (8) ◽  
pp. 850-856
Author(s):  
Ankit Shukla ◽  
Chi Braunreiter
Keyword(s):  
Molecular Weight ◽  
Premature Infant ◽  
Critically Ill ◽  
Premature Infants ◽  
Low Molecular Weight Heparin ◽  
Inferior Vena ◽  
Antithrombin Iii ◽  
Vena Cava ◽  
Low Molecular Weight ◽  
Optimal Target

The optimal antithrombin (AT) activity for low-molecular-weight heparin efficacy and the benefits of antithrombin III (ATIII) supplementation in premature infants diagnosed with venous thromboembolism are unknown. Currently, there are no neonatal-specific guidelines directing the appropriate target AT activity during supplementation. This case report describes a critically ill premature infant with a progressive, occlusive inferior vena cava thrombus who received supplemental ATIII during enoxaparin treatment. The patient did not achieve therapeutic anti-Xa levels despite increasing enoxaparin dosing to 3 mg/kg every 12 hours. ATIII supplementation sufficient to attain an AT activity of >40%, in combination with an enoxaparin dosing of >2 mg/kg every 12 hours, was needed to achieve therapeutic anti-Xa levels. Future large studies are needed to determine if there is an optimal target AT activity for critically ill premature infants.

Sign in / Sign up

Export Citation Format

Share Document